

Adherium will provide its Hailie® Smartinhaler® for an AstraZeneca clinical trial

Highlights:

- AstraZeneca has selected Adherium's Hailie® Smartinhaler® platform for a clinical trial.
- Hailie® technology to aid the collection of objective data for inhaler use in a clinical trial.
- Contract valued at \$1.1M

Melbourne, Australia – 24 May 2024: Adherium Limited ("Adherium" or "the Company"; ASX:ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, today announced that AstraZeneca has selected its Hailie® Smartinhaler® platform for a clinical trial. This contract is valued at \$1.1M over the course of three years.

AstraZeneca's inhaled medication use will be recorded and transferred via Hailie Smartinhaler devices.

Adherium CEO, Dr. Paul Mastoridis, said: *"This agreement underscores Adherium's strategic commitment to enhancing patient care through advanced technology. Our Hailie® platform is designed to ensure precise monitoring and support for patients with respiratory diseases, facilitating the pursuit of tailored therapy."*

Adherium will be providing Hailie® Smartinhalers®, Hailie® app and Platform for the trial, allowing for accurate tracking of inhaler medication use through the selected eCOA (Electronic Clinical Outcome Assessment) devices.

- ENDS -

This ASX announcement was approved and authorised for release by the Board of Adherium.

Investor Enquiries

Dr. Paul Mastoridis
Adherium Limited
Chief Executive Officer
investors@adherium.com

Media Enquiries:

Haley Chartres
HACK
Director
haley@hck.digital



ASX Release

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at www.adherium.com